Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults

Journal of Infectious Diseases

Volumn 180, Issue 6, 1999, Pages 2023-2026

  Hasan, Muhammad S ^a   Agosti, Jan M ^b   Reynolds, Kara K ^a   Tanzman, Esther ^a   Treanor, John J ^a   Evans, Thomas G ^a,c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b AMGEN INC   (United States)

^c Box 689 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE; VACCINATION;

EID: 0032759065     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315129     Document Type: Article

References (15)

1. 1. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209-14.
2. 2. West DJ. Clinical experience with hepatitis B vaccines. Am J Infect Control 1989;17:172-80.
3. 3. Alimonos K, Nafziger AN, Murray J, Bertino JS Jr. Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness? [see comments]. Clin Infect Dis 1998;26:566-71.
4. 4. Rosman AS, Lieber CS. Improving the response to hepatitis B vaccine. Infect Med 1999:205-10.
5. 5. Allison AC. The mode of action of immunological adjuvants. Dev Biol Stand 1998;92:3-11.
6. 6. Tarr PE, Lin R, Mueller EA, Kovarik JM, Guillaume M, Jones TC. Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine 1996;14:1199-204.
7. 7. Disis ML, Bernhard H, Shiota FM, et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996;88:202-10.
8. 8. Fischer HG, Frosch S, Reske K, Reske-Kunz AB. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class 11 molecules and to augmented antigen presentation function. J Immunol 1988;141:3882-8.
9. 9. Markowicz S, Engleman EG. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 1990;85:955-61.
10. 10. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group [see comments]. N Engl J Med 1997;336:1855-9.
11. 11. Hess G, Kreiter F, Kosters W, Deusch K. The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients. J Viral Hepat 1996;3:149-53.
12. 12. Weiss WR, Ishii KJ, Hedstrom RC, et al. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 1998;161:2325-32.
13. 13. Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA. Cytokine-inadjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol 1997;158:3947-58.
14. 14. Kedar E, Palgi O, Golod G, Babai I, Barenholz Y. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. J Immunother 1997;20:180-93.
15. 15. McLaughlin JP, Abrams S, Kantor J, et al. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity. J Immunother 1997;20:449-59.